All Categories - SeekIn
June 18, 2025 ·
San Diego, June 18, 2025 -- Biotecgen (Colombia) and OncoInv (The Netherlands) have joined forces...
June 2, 2025 ·
San Diego, May 26, 2025 -- A groundbreaking study published in the Journal of Molecular...
CHICAGO, United States, May 30, 2025 - SeekIn Inc., a leader in blood-based cancer early...
Brussels, Belgian - May 18-22, 2025 SeekIn Inc., a leader in blood-based cancer early detection...
Amsterdam, the Netherlands - May 14-15, 2025 SeekIn Inc., a leader in blood-based cancer early...
April 8, 2025 ·
Longevity Medical Institute™ (LMI), Mexico's premier center for regenerative medicine, anti-aging...
BIOS (Pakistan) and OncoInv (The Netherlands) have joined forces to make multi-cancer early...
January 24, 2025 ·
San Diego, January 22, 2025 — SeekIn Inc, a leader in blood-based cancer early detection and...
January 22, 2025
SAN DIEGO, United States, January 22, 2025 -- SeekIn Inc, aleader in blood-based cancer early...
December 30, 2024
SAN DIEGO, United States, December 30, 2024 -- SeekIn Inc, a leader in blood-based cancer early...
San Diego, California, USA - November 13-16, 2024 SeekIn Inc., a leader in blood-based cancer...
December 17, 2024
Amsterdam, The Netherlands - October 26, 2024 Dr. Mao Mao, CEO of SeekIn and a globally...
Chicago, October 15-16, 2024 — At the Precision Oncology & Diagnostics, Bernadette Toner, CEO of...
SeekIn announced a innovative two-step multi-cancer screening strategy at the Early Detection of...
October 15, 2024
OncoInv and Healthcare Systems Mexico have joined forces to make multi cancer early detection...
August 17, 2024 ·
SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, announced...
Excellion (Nigeria) and OncoInv (The Netherlands) have joined forces to make multi cancer early...
São Paulo, Brazil – First Saúde, led by renowned oncologist Dr. Raphael Brandão, announces a...
In Poland, cancers are detected in late stages, which makes effective treatment impossible....
Two Sample Types, Three Different Platforms, Six Independent Cohorts of ~12,000 Cancer Patients...